Background The effectiveness and safety of dabigatran etexilate (DE) have not been
elucidated thoroughly in clinical practice for Japanese patients with non-valvular atrial …

Background In “real-world” practice, anticoagulant therapy is indicated for patients whose
clinical profiles are not addressed in randomized clinical trials. We assessed the …

Essentials• Bleeding is a common cause of hospital admission and readmission in oral
anticoagulant users.• Patients with dabigatran and warfarin were included to assess hospital …

Background Economic evaluation of dabigatran, a new anti-antithrombotic agent, is done
mostly in Western countries. It remains to be seen whether dabigatran will be cost effective …

Background The incidence of thromboembolic events in patients on dabigratran is low
compared to warfarin, but the consequences of these events can be catastrophic. Monitoring …

Introduction Dabigatran etexilate (DE) is a direct oral thrombin inhibitor. Dabigatran
excretion is 80% renal, and exposure increases with the severity of renal failure. The FDA …

Background: A recommendation for dosage adjustment of dabigatran etexilate, a prodrug of
dabigatran, seems to be desirable based on creatinine clearance to avoid bleeding and …

Essentials• Prothrombin and partial thromboplastin time (PT/PTT) measure direct oral
anticoagulants (DOACs).• PT, PTT and specific tests for DOACs were performed on patients …

Dabigatran is a new direct competitive inhibitor of thrombin and is equally effective and safe
as warfarin in the prevention of thromboembolism in patients with nonvalvular atrial …

Introduction Dabigatran is effective and widely used to prevent ischemic stroke and systemic
embolism (SE) in patients with atrial fibrillation (AF). Chronic kidney disease (CKD) also has …